Novo Nordisk A/S is confident that 3 mg liraglutide will clear FDA's efficacy hurdles for obesity therapies even though that dose hit the less preferred of the agency's two obesity benchmarks in a Phase IIIa trial in obese diabetics.

The company also expects aggregate data from all obesity and diabetes trials of liraglutide will obviate the need for a long-term cardiovascular outcomes study of the 3 mg dose.